Recce Pharmaceuticals Ltd (ASX: RCE) - Share Price

- Current share price for RCE : $0.330

Recce Pharmaceuticals Ltd (RCE) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian late-stage clinical biotech company focused on the development and commercialisation of a new class of Synthetic Anti-infectives designed to address the urgent global health problem of antimicrobial resistant (AMR) superbugs.

RCE General Information ⁺

ASX Code	RCE
Website	http://recce.com.au
Industry/Sector	Pharmaceuticals
Market Cap ($M)	100
RCE Share Price	$0.330
Day High	$0.330
Day Low	$0.320
Last Close	$0.330
RCE Share Price Movement	- ( No change )

Prices as at 16:40, 6 Nov 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Recce Pharmaceuticals Ltd (RCE) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Recce Pharmaceuticals Ltd (RCE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Recce Pharmaceuticals Ltd (RCE) price-sensitive announcements

RCE - Quarterly Activities/Appendix 4C Cash Flow Report

Recce Pharmaceuticals Ltd’s Quarterly Cash Flow Statement & Operational Highlights for the

Recce Pharmaceuticals Ltd (RCE)
30 Oct 2026 | 12:04 PM

RCE - License and Commercialisation Agreement in AUS/NZ for R327G

Recce Pharmaceuticals Ltd announced a binding exclusive licence and commercialisation agre

Recce Pharmaceuticals Ltd (RCE)
22 Oct 2026 | 9:45 AM

RCE - Independent Review of Indonesian Phase 3 R327G Trial Data

Recce Pharmaceuticals Ltd announced that an independent Data Monitoring Committee (DMC) wi

Recce Pharmaceuticals Ltd (RCE)
20 Oct 2026 | 11:19 AM

RCE - Amendments to Debt Facility with Avenue Capital Group

Recce Pharmaceuticals Ltd announced an amendment to its existing secured debt facility wit

Recce Pharmaceuticals Ltd (RCE)
16 Oct 2026 | 3:02 PM

Recce Pharmaceuticals Ltd (RCE) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	Final Director's Interest Notice - Mr McKeough	6 Nov 2026 5:04PM	$0.330	$0.330	fallen by 0%
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	Results of Meeting	6 Nov 2026 1:27PM	$0.320	$0.330	risen by 3.13%
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	AGM Presentation	6 Nov 2026 8:24AM	$0.330	$0.330	fallen by 0%
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	Retirement of Mr Alistair McKeough as Non-Executive Director	4 Nov 2026 6:49PM	$0.335	$0.330	fallen by 1.49%
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	Options Prospectus	4 Nov 2026 9:38AM	$0.335	$0.330	fallen by 1.49%
Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID	Health Care	$101	Cleansing Notice	30 Oct 2026 5:39PM	$0.360	$0.330	fallen by 8.33%

RCE Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$20.00	42.90%	0.00%	0.0%
2027F	C2	-$14.00	170.80%	0.00%	0.0%
2026A	-$14.96	-$5.20	-42.80%	0.00%	0.0%

RCE Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Clarity Pharmaceuticals Ltd (CU6)	$597M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,946M	-0.7857	0.2462	0.9655	99.8711	80.1379	40.7719	0.00%	1.42%	1.68%
Recce Pharmaceuticals Ltd (RCE)	$101M	-0.4281	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

RCE Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	-5.71	0.00
Market	0.30	13.40	1.03	0.75
Sector	0.78	33.40	2.19	2.23

RCE Directors

Name	Position	Start Date
Dr Alan William Dunton	Chief Medical Advisor, Non-Executive Director	14 Jul 2020
Ms Michele Keryn Dilizia	Chief Scientific Officer, Executive Director	23 Jun 2015
Mr Alistair Gregory McKeough	Company Secretary, Non-Executive Director	1 Sep 2022
Dr John Prendergast	Executive Chairman, Executive Director	23 Apr 2018
Dr Justin Leigh Ward	Executive Director	9 Jul 2019
Mr James Hamilton Bray Graham	Managing Director, Executive Director, Chief Executive Officer	23 Jun 2015

Recce Pharmaceuticals Ltd (RCE) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
31 Jul 2026	GRAHAM, James	Buy	Indirect Shares	25,000	$0.400	$10,000.000
31 Jul 2026	DUNTON, Alan	Buy	Indirect Shares	37,500	$0.400	$15,000.000
31 Jul 2026	WARD, Justin	Buy	Direct Shares	75,000	$0.400	$30,000.000

See all changes in directors' interest & trades for Recce Pharmaceuticals Ltd (RCE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RCE Management

Name	Position
Justin Reynolds	Chief Financial Officer
Maggie Niewidok	Company Secretary
Arthur Kollaras	Principal Engineer & Head of Manufacturing

RCE Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Recce Pharmaceuticals Ltd (RCE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
38,428,311 (22.11%)	Graham John Hamilton Melrose & Olga Mary Melrose
39,561,800 (13.68%)	Gavin William Brown
24,705,816 (8.57%)	FIL Limited

RCE Calendar of Events

Date	Event
30 August 2027	Report (Annual)
30 August 2027	Report (Prelim)
26 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us